You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-c-Met (HGFR)-Altiratinib
Altiratinib

Chemical Structure : Altiratinib

CAS No.: 1345847-93-9

Altiratinib (DCC-2701, DCC2701)

Catalog No.: PC-38624Not For Human Use, Lab Use Only.

Altiratinib (DCC-2701) is a potent c-MET/TIE-2/VEGFR inhibitor with IC50 of 2.7 nM (MET WT), 8.0 nM (TIE2 kinase) and 9.2 nM (VEGFR2), also potently inhibits oncogenic MET mutations in the switch region (residues 1228, 1230, and 1250) with IC50 range of 0.37-6 nM.

Packing Price Stock Quantity
25 mg $148 In stock
50 mg $228 In stock
100 mg $388 In stock
200 mg $588 In stock
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Altiratinib (DCC-2701) is a potent c-MET/TIE-2/VEGFR inhibitor with IC50 of 2.7 nM (MET WT), 8.0 nM (TIE2 kinase) and 9.2 nM (VEGFR2), also potently inhibits oncogenic MET mutations in the switch region (residues 1228, 1230, and 1250) with IC50 range of 0.37-6 nM.
Altiratinib (DCC-2701) also potently inhibited TRKA, TRKB, and TRKC (NTRK3) kinases with IC50 values of 0.85 nM, 4.6 nM, and 0.83 nM, respectively.
Altiratinib (DCC-2701) is >10-fold selective for MET versus FMS and KIT, and >50-fold selective for MET versus ABL1, FYN, HER1 (EGFR), p38a (MAPK14), PDGFRa, PDGFRb, RET, and SRC.
Altiratinib (DCC-2701) inhibited HGF-stimulated MET phosphorylation in HUVECs, exhibiting an IC50 of 2.3 nM, inhibited VEGFR2 phosphorylation with an IC50 of 4.7 nM in VEGF-stimulated HUVECs.
Altiratinib (DCC-2701) exhibits robust pharmacology in tumor models driven by genomic MET mutation as well as in models of microenvironment activation of MET.

Physicochemical Properties

M.Wt 510.47
Formula C26H21F3N4O4
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N-[4-[[2-[(Cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

References

1. Smith BD, et al. Mol Cancer Ther. 2015 Sep;14(9):2023-34.

2. Kwon Y, et al. Oncogene. 2015 Jan 8;34(2):144-53.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: